Distribution and Determinants of Suspected Adverse Events among COVID like Illness (CLI) Patients with Different Comorbidities

Authors

  • Shahana Sarwar Lecturer, Department of Pharmacology, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh https://orcid.org/0000-0001-7550-0219
  • Muhammad Tanvir Mohith Assistant Professor, Department of Medicine, OSD, Directorate General of Health Services, Attached Sylhet MAG Osmani Medical College, Sylhet, Bangladesh https://orcid.org/0000-0001-8458-2308
  • Muhammad Marnush OSD, DGHS, Attached Phase B resident [MD in Pharmacology], Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; https://orcid.org/0009-0009-5466-2222
  • Muhammad Nafees Hussain 4 Registrar, Department of Medicine, National Institute of Diseases of Chest and Hospital, Dhaka, Bangladesh; https://orcid.org/0009-0006-4506-1634
  • Md Sayedur Rahman Rahman Chairman, Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh https://orcid.org/0000-0002-5960-0161
  • Tahmina Begum Assistant Professor, Department of Pathology, Mugda Medical College, Dhaka

DOI:

https://doi.org/10.3329/jninb.v9i1.65382

Keywords:

Distribution and Determinants, Suspected Adverse Events, COVID like Illness (CLI) Patients, Different Comorbidities

Abstract

Background: Several drugs were administered to patients with COVID-19, focusing on their antiviral, immunomodulatory, or anti-inflammatory actions, which could potentially present risk since most of these medicines have the potential to cause numerous adverse effects.

Objective: This study aimed to observe the incidence of suspected adverse events of selected medicines among COVID-like ill (CLI) patients.

Methodology: A prospective analysis was performed from February 15, 2021, to June 15, 2021, upon 223 CLI patients. CLI patients were enrolled from the National Institute of Diseases of the Chest and Hospital. The incidence of suspected adverse events were assessed among CLI patients, the laboratory investigations values of SGPT, RBS, serum electrolytes, and serum creatinine of day one and day five and interpreted the 12-lead ECG tracing paper of the same days assessed hepatotoxicity, nephrotoxicity, cardiotoxicity, and metabolic disorders.

Results: The result showed the incidence of adverse events was 21.5% in CLI patients. Only the incidence of hepatotoxicity was more (12.55%) among CLI patients but statistically not significant (p > 0.05). In CLI patients who had co-morbidities, the incidence of adverse events was relatively less and only a significant difference was seen among diabetes mellitus patients (p ≤ 0.05).

Conclusion: This study showed that the rate of adverse events was present in CLI patients when treated with the same specific drug of interest in addition to other medicines they received.

Journal of National Institute of Neurosciences Bangladesh, January 2023;9(1):35-41

Downloads

Download data is not yet available.
Abstract
56
PDF
55

Downloads

Published

2023-10-04

How to Cite

Sarwar, S., Mohith, M. T. . ., Marnush, M. . ., Hussain, M. N. . . ., Rahman, M. S. R., & Begum, T. (2023). Distribution and Determinants of Suspected Adverse Events among COVID like Illness (CLI) Patients with Different Comorbidities. Journal of National Institute of Neurosciences Bangladesh, 9(1), 35–41. https://doi.org/10.3329/jninb.v9i1.65382

Issue

Section

Original Research Articles